|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
Our meta-analysis of mTOR rs2295080 and cancer risk provided further evidence that mTOR SNPs might modulate cancer susceptibility.
|
25654238 |
2015 |
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
Recently, a functional polymorphism (rs2295080 T>G) in the promoter of MTOR has been shown to influence its expression and confer susceptibility to cancer.
|
25776475 |
2015 |
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
Our meta-analysis of mTOR rs2295080 and cancer risk provided further evidence that mTOR SNPs might modulate cancer susceptibility.
|
25654238 |
2015 |
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
Recently, a functional polymorphism (rs2295080 T>G) in the promoter of MTOR has been shown to influence its expression and confer susceptibility to cancer.
|
25776475 |
2015 |
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
Our meta-analysis results showed that the wild genotype TT of rs2295080 polymorphism was associated with increased cancer risk under dominant model (OR = 1.24, 95%CI: 1.12-1.36, p<0.0005) in Chinese but not with clinical outcome parameters, while the TT genotype of rs11121704 was associated with poor clinical outcome parameters (OR = 1.53, 95%CI: 1.01-2.32, p = 0.044), such as death, metastasis and resistance to chemotherapy.
|
24816861 |
2014 |
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
Our meta-analysis results showed that the wild genotype TT of rs2295080 polymorphism was associated with increased cancer risk under dominant model (OR = 1.24, 95%CI: 1.12-1.36, p<0.0005) in Chinese but not with clinical outcome parameters, while the TT genotype of rs11121704 was associated with poor clinical outcome parameters (OR = 1.53, 95%CI: 1.01-2.32, p = 0.044), such as death, metastasis and resistance to chemotherapy.
|
24816861 |
2014 |
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
When estimated these two SNPs together, the combined genotypes with 2-4 risk alleles (rs2295080 T and rs7254617 A alleles) were associated with an increased risk of PCa compared with 0-1 risk alleles, which was more pronounced among subgroups of age >71 years, smokers, drinkers and no family history of cancer.
|
22815832 |
2012 |
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
When estimated these two SNPs together, the combined genotypes with 2-4 risk alleles (rs2295080 T and rs7254617 A alleles) were associated with an increased risk of PCa compared with 0-1 risk alleles, which was more pronounced among subgroups of age >71 years, smokers, drinkers and no family history of cancer.
|
22815832 |
2012 |
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Here, we discovered, for the first time, that rs2295079 (-78C/G) and rs2295080 (-141G/T) formed linkage haplotypes, with Ht1 (-78C/-141G) and Ht2 (-78G/-141T) being dominant, which were associated with distinct susceptibility to breast cancer, response to paclitaxel, and clinical outcomes in breast cancer.
|
31467112 |
2019 |
|
Stomach Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
In conclusion, the polymorphisms of the two loci, PIK3R3 rs7536272 and mTOR rs2295080, on the PI3K/AKT/mTOR signaling pathway genes are associated with genetic susceptibility to gastric cancer in Chinese population.
|
29332342 |
2019 |
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
Here, we discovered, for the first time, that rs2295079 (-78C/G) and rs2295080 (-141G/T) formed linkage haplotypes, with Ht1 (-78C/-141G) and Ht2 (-78G/-141T) being dominant, which were associated with distinct susceptibility to breast cancer, response to paclitaxel, and clinical outcomes in breast cancer.
|
31467112 |
2019 |
|
Malignant neoplasm of stomach
|
|
0.020 |
GeneticVariation
|
BEFREE |
In conclusion, the polymorphisms of the two loci, PIK3R3 rs7536272 and mTOR rs2295080, on the PI3K/AKT/mTOR signaling pathway genes are associated with genetic susceptibility to gastric cancer in Chinese population.
|
29332342 |
2019 |
|
Neoplasm Metastasis
|
|
0.020 |
GeneticVariation
|
BEFREE |
We detected no significant correlations between rs2536 polymorphism and the clinical parameters of breast cancer patients, while rs2295080 polymorphism was associated with lymph node (LN) metastasis.
|
27533457 |
2016 |
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
In parallel, the significant effects were observed between mTOR rs2295080 polymorphism and breast cancer risk in the allele, codominant, and recessive models (P < 0.05).
|
27533457 |
2016 |
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
In parallel, the significant effects were observed between mTOR rs2295080 polymorphism and breast cancer risk in the allele, codominant, and recessive models (P < 0.05).
|
27533457 |
2016 |
|
Neoplasm Metastasis
|
|
0.020 |
GeneticVariation
|
BEFREE |
Our meta-analysis results showed that the wild genotype TT of rs2295080 polymorphism was associated with increased cancer risk under dominant model (OR = 1.24, 95%CI: 1.12-1.36, p<0.0005) in Chinese but not with clinical outcome parameters, while the TT genotype of rs11121704 was associated with poor clinical outcome parameters (OR = 1.53, 95%CI: 1.01-2.32, p = 0.044), such as death, metastasis and resistance to chemotherapy.
|
24816861 |
2014 |
|
Prostate carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
In the single-locus analysis, we found a significantly increased risk of PCa associated with mTOR rs2536 CT/CC and rs1034528 CG/CC genotypes [adjusted OR = 1.42 (1.13-1.78), P = 0.003 and 1.29 (1.07-1.55), P = 0.007), respectively], compared with their common homozygous genotypes, whereas mTOR rs2295080 GT/GG genotypes were associated with a decreased risk of PCa [adjusted OR = 0.76 (0.64-0.92), P = 0.003], compared with wild-type TT genotypes.
|
23940798 |
2013 |
|
Stomach Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
The mTOR promoter polymorphism rs2295080 was significantly associated with GC risk.
|
23555892 |
2013 |
|
Malignant neoplasm of prostate
|
|
0.020 |
GeneticVariation
|
BEFREE |
In the single-locus analysis, we found a significantly increased risk of PCa associated with mTOR rs2536 CT/CC and rs1034528 CG/CC genotypes [adjusted OR = 1.42 (1.13-1.78), P = 0.003 and 1.29 (1.07-1.55), P = 0.007), respectively], compared with their common homozygous genotypes, whereas mTOR rs2295080 GT/GG genotypes were associated with a decreased risk of PCa [adjusted OR = 0.76 (0.64-0.92), P = 0.003], compared with wild-type TT genotypes.
|
23940798 |
2013 |
|
Malignant neoplasm of stomach
|
|
0.020 |
GeneticVariation
|
BEFREE |
The mTOR promoter polymorphism rs2295080 was significantly associated with GC risk.
|
23555892 |
2013 |
|
Malignant neoplasm of prostate
|
|
0.020 |
GeneticVariation
|
BEFREE |
When estimated these two SNPs together, the combined genotypes with 2-4 risk alleles (rs2295080 T and rs7254617 A alleles) were associated with an increased risk of PCa compared with 0-1 risk alleles, which was more pronounced among subgroups of age >71 years, smokers, drinkers and no family history of cancer.
|
22815832 |
2012 |
|
Prostate carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
When estimated these two SNPs together, the combined genotypes with 2-4 risk alleles (rs2295080 T and rs7254617 A alleles) were associated with an increased risk of PCa compared with 0-1 risk alleles, which was more pronounced among subgroups of age >71 years, smokers, drinkers and no family history of cancer.
|
22815832 |
2012 |
|
Bladder Neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
Additionally, mTOR rs2295080 variant notably increased the risk of BC (OR=2.25, 95 % CI=1.50-3.38, p<0.0001, GT vs GG; OR=4.75, 95 % CI=2.80-8.06, p<0.0001, TT vs GG; OR=3.10, 95 % CI=2.34-4.10, p<0.0001, T vs G).
|
29383014 |
2018 |
|
Malignant neoplasm of urinary bladder
|
|
0.010 |
GeneticVariation
|
BEFREE |
Additionally, mTOR rs2295080 variant notably increased the risk of BC (OR=2.25, 95 % CI=1.50-3.38, p<0.0001, GT vs GG; OR=4.75, 95 % CI=2.80-8.06, p<0.0001, TT vs GG; OR=3.10, 95 % CI=2.34-4.10, p<0.0001, T vs G).
|
29383014 |
2018 |
|
Carcinoma of bladder
|
|
0.010 |
GeneticVariation
|
BEFREE |
Additionally, mTOR rs2295080 variant notably increased the risk of BC (OR=2.25, 95 % CI=1.50-3.38, p<0.0001, GT vs GG; OR=4.75, 95 % CI=2.80-8.06, p<0.0001, TT vs GG; OR=3.10, 95 % CI=2.34-4.10, p<0.0001, T vs G).
|
29383014 |
2018 |